Significance of Antistriational Antibodies for Immune Checkpoint Inhibitor-Related Myositis: Comment on the Article by Aldrich et al
- PMID: 33682362
- DOI: 10.1002/art.41713
Significance of Antistriational Antibodies for Immune Checkpoint Inhibitor-Related Myositis: Comment on the Article by Aldrich et al
Comment in
-
Reply.Arthritis Rheumatol. 2021 Aug;73(8):1564. doi: 10.1002/art.41714. Epub 2021 Jun 29. Arthritis Rheumatol. 2021. PMID: 33682370 No abstract available.
Comment on
-
Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors.Arthritis Rheumatol. 2021 May;73(5):866-874. doi: 10.1002/art.41604. Epub 2021 Apr 1. Arthritis Rheumatol. 2021. PMID: 33258544
References
-
- Aldrich J, Pundole X, Tummala S, Palaskas N, Andersen CR, Shoukier M, et al. Inflammatory myositis in cancer patients receiving immune checkpoint inhibitors. Arthritis Rheumatol 2021;73:866-74.
-
- Suzuki S, Ishikawa N, Konoeda F, Seki N, Fukushima S, Takahashi K, et al. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology 2017;89:1127-34.
-
- Seki M, Uruha A, Ohnuki Y, Kamada S, Noda T, Onda A, et al. Inflammatory myopathy associated with PD-1 inhibitors. J Autoimmun 2019;100:105-13.
-
- Kufukihara K, Watanabe Y, Inagaki T, Takamatsu K, Nakane S, Nakahara J, et al. Cytometric cell-based assays for anti-striational antibodies in myasthenia gravis with myositis and/or myocarditis. Sci Rep 2019;9:5284.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
